| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
16,371 |
15,556 |
$19.60M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
34,741 |
28,648 |
$5.83M |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
1,108 |
1,036 |
$1.53M |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
23,302 |
21,617 |
$752K |
| 92134 |
|
33,637 |
31,713 |
$648K |
| 92250 |
|
21,980 |
21,171 |
$643K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
11,863 |
11,545 |
$464K |
| J9035 |
Injection, bevacizumab, 10 mg |
4,068 |
3,622 |
$345K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,150 |
3,116 |
$122K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,361 |
2,306 |
$116K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,799 |
1,784 |
$115K |
| 92235 |
|
1,644 |
1,599 |
$110K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
1,924 |
1,917 |
$99K |
| Q5124 |
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg |
12 |
12 |
$6K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
42 |
42 |
$4K |
| 92225 |
|
78 |
75 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
94 |
94 |
$3K |
| 92226 |
|
115 |
69 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
25 |
24 |
$1K |
| 76512 |
|
29 |
24 |
$1K |
| J7999 |
Compounded drug, not otherwise classified |
70 |
68 |
$1K |